Profil
Ashleigh Barreto is currently the Head of Investor Relations and Corporate Communications at Viracta Therapeutics, Inc. Prior to this, she worked as the Director of Communications and Investor Relations at Adamas Pharmaceuticals LLC and as the Head of Investor and Media Relations at XOMA Corp.
Postes actifs de Ashleigh Barreto
| Sociétés | Poste | Début |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Investor Relations Contact | 01/10/2021 |
Anciens postes connus de Ashleigh Barreto
| Sociétés | Poste | Fin |
|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Investor Relations Contact | 01/12/2018 |
| XOMA CORPORATION | Investor Relations Contact | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| XOMA CORPORATION | Health Technology |
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
